Base-Case Model Results: Average Per-Patient Lifetime Health and Cost Outcomes by Patient Subgroup.

<p>DCC indicates decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; PR, peginterferon alfa-2a plus ribavirin; QALY, quality-adjusted life-year; TVR, telaprevir.</p>a<p>Modeled cases of cirrhosis that developed following treatment.</p>b<p>Due to rounding, ICERs differ slightly from calculations using costs, life-years, and QALYs shown in this table.</p>c<p>One treatment dominates another if it exhibits more QALYs at a lower total cost.